Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17942948 | 0.88 | RAB9A (0.50) | RAB9ANPC1HTTPKMKDM4E | |
| SCHEMBL17942947 | 0.84 | RAB9A (0.49) | RAB9ANPC1HTTPKMKDM4E | |
| SCHEMBL13494175 | 0.84 | RAB9A (0.50) | RAB9ANPC1HTTPKMKDM4E | |
| SCHEMBL17942937 | 0.80 | HPGD (0.54) | RAB9ANPC1HTTPKMKDM4E | |
| SCHEMBL13494166 | 0.80 | GPR35 (0.41) | KDM4EHSD17B10MEN1KMT2AALDH1A1 | |
| SCHEMBL17942942 | 0.77 | — | — | |
| SCHEMBL24983245 | 0.72 | SLC16A3 (0.58) | RAB9ANPC1HTTPKMKDM4E | |
| SCHEMBL13494180 | 0.69 | KDR (0.37) | NPC1HTTKDM4EHSD17B10MEN1 | |
| SCHEMBL14405907 | 0.67 | MAOB (0.60) | KDM4EGAAMEN1KMT2AALDH1A1 | |
| SCHEMBL530998 | 0.67 | GPR35 (0.68) | KDM4EHSD17B10TSHRALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11175204-B1 | 7-hydroxycoumarin-based cell-tracking reagents | Life Technologies Corporation (US) | 2021-11-16 | — | — | US | disclosed |
| US-9400273-B1 | 7-hydroxycoumarin-based cell-tracking reagents | Life Technologies Corporation (US) | 2016-07-26 | — | — | US | disclosed |
| US-20100029017-A1 | Mono-chlorinated hydroxycoumarin conjugates | BECTON, DICKINSON AND COMPANY | 2010-02-04 | — | — | US | disclosed |
| US-20100029017-A1 | Mono-chlorinated hydroxycoumarin conjugates | BECTON, DICKINSON AND COMPANY | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029017-A1 | Mono-chlorinated hydroxycoumarin conjugates | CLSPN, CLTC, HACD3 | RAB9A 3902/4885NPC1 3516/4885HTT 1115/4885 |
| US-11175204-B1 | 7-hydroxycoumarin-based cell-tracking reagents | MKI67, DCX, CDK7 | RAB9A 1583/4885NPC1 1705/4885HTT 551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.